Breaking News, Collaborations & Alliances

Ortho-McNeil Enters Diabetes Pact

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) has signed an exclusive agreement with Diamyd Medical AB to develop and commercialize Diamyd’s GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) has signed an exclusive agreement with Diamyd Medical AB to develop and commercialize Diamyd’s GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions. This investigational therapy is currently being evaluated in Phase III studies in for its ability to delay or prevent progression of the disease and its associated complications by delaying or preventing further destruction of pancreatic islet bet...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters